Hoxworth Blood Center Celebrates 10 Years of FACT Accreditation
Hoxworth Blood Center at the University of Cincinnati (UC) is celebrating 10 years of FACT (Foundation of the Accreditation of Cellular Therapy) accreditation. The organization has been recognized for this achievement and for its dedication and commitment to high-quality stem cell transplantation and cellular therapy.
"Please join me in applauding our Cellular Therapy Team lead by Dr. Tom Leemhuis in achieving this milestone honor, said Ronald Sacher, MD, Hoxworth's director and a professor of medicine and pathology at the UC College of Medicine. "The hard work and dedication of this team is helping to advance medical treatment and save lives in the Tristate every day.
FACT is a non-profit corporation co-founded in 1994 by the International Society for Cellular Therapy (ISCT) and the American Society of Blood and Marrow Transplantation (ASBMT) for the purposes of voluntary inspection and accreditation in the field of cellular therapy. The major objective of FACT is to promote high-quality patient care and laboratory performance in the belief that a valid accreditation must assess clinical, collection, and the laboratory components of the field.
Accreditation is awarded after successful documentation of compliance with the current standards. A team of inspectors who are qualified by training and experience carry out on-site inspections. The inspection process is quality-oriented and follows the FDAs rules for current Good Tissue Practice (cGTP).
Hoxworth Blood Center was founded in 1938 and serves 31 hospitals in 17 counties in southwestern Ohio, Northern Kentucky and southeastern Indiana. Annually, Hoxworth collects more than 90,000 units of blood from local donors to help save the lives of patients in area hospitals.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.